Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  Ectoin
Research reference — not for sale

Ectoin

B
lead outcome
Topical: barrier function / TEWL reduction
grades vary by outcome ↓
Small molecule (non-peptide)
also called — (S)-2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid · THP(B) — tetrahydropyrimidine · extremolyte · INCI: Ectoin
skin appearance (cosmetic)barrier supporthydrationsoothing (appearance of redness)antioxidant

Ectoin is a lawful cosmetic ingredient worldwide. Vallydia uses it in cosmetic serums at concentrations supported by clinical trials (0.5–2%) with appearance-only claims. Reference science below includes both topical cosmetic and medical-device uses (atopic dermatitis, rhinitis); only the cosmetic barrier/hydration/soothing-appearance framing is relevant to the sellable product.

In brief

Ectoin is a small (142 Da) amino-acid-derived "extremolyte" — a molecule that desert bacteria in salt lakes manufacture to survive extreme heat, UV, and osmotic stress. On skin it works as an osmolyte, forming a protective water shell around cells that stabilises the barrier, reduces transepidermal water loss, calms the appearance of redness, and defends against environmental stressors. It's exceptionally gentle (hypoallergenic, pregnancy-friendly) and — unlike many trend molecules — it's small enough to genuinely penetrate skin. Honest limit: ectoin protects and hydrates, but does not build collagen or replace retinol. It's a partner, not a hero.

Legal standing, by region
International
Lawful cosmetic ingredient

Topical Ectoin is a lawful cosmetic ingredient globally, including EU (Regulation (EC) 1223/2009), UK, US, and Asia. CosIng-listed. Also registered as an active in EU medical-device products (e.g. atopic dermatitis creams) — these are regulated separately under MDR 2017/745, not as cosmetics. Consumer serum formulations typically use 0.5–2%.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: barrier function / TEWL reduction
Effect size varies with vehicle and baseline barrier state; well-established but not head-to-head vs ceramide-based formulas in most trials
Multiple placebo-controlled clinical trials over 20+ years; consistent TEWL reductions of 15–72% depending on skin state and formulation · Measurable reduction in transepidermal water loss; barrier stabilisation
B
Skin hydration
Effect works via osmolyte mechanism (water-shell around cells) rather than humectant (like HA)
Controlled trials with 0.5–7% ectoin creams and lotions · Measurable increase in stratum corneum hydration; sustained over weeks of use
B
Redness and appearance of sensitive/reactive skin
Adjunct effect; not a treatment for underlying skin conditions
Controlled trials showing measurable reduction in visible erythema and subjective irritation scores; use in sensitive-skin adjacent categories · Reduction in appearance of redness (~38% in some trials)
B
Atopic dermatitis (medical use, not cosmetic)
Medical device territory in EU, not cosmetic; do not conflate medical claims with topical cosmetic serum framing
Multiple clinical trials with 5.5–7% ectoin cream (branded medical device products); comparable to low-potency corticosteroid in some studies · Improvement in SCORAD and symptoms
B
Protection against UV and pollution-induced skin stress
Not a sunscreen; adjunct to UV protection, not replacement
In-vitro on skin cells and controlled human studies with UV/pollution exposure models · Measurable protection of cell viability and reduction of oxidative markers
B
Anti-wrinkle / collagen-building claims
Ectoin protects and hydrates; it does not build collagen or replace retinol. Framing as an anti-aging hero is a marketing overstatement.
Limited direct evidence; effect largely inferred from barrier/hydration benefits · Modest at best, indirect
D
Safety (topical)
Hypoallergenic, pregnancy-friendly, no known conflicts with other cosmetic actives; suitable for infants and reactive skin
Decades of cosmetic use; extensive tolerability data · Exceptionally well tolerated
—
Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • supports the appearance of a healthy skin barrier
  • for the appearance of hydrated, comfortable-feeling skin
  • helps reduce the look of redness
  • for the appearance of skin that feels calm and soothed
  • antioxidant
✕ Not allowed (medicinal)
  • treats atopic dermatitis
  • treats eczema
  • repairs the skin barrier
  • anti-inflammatory
  • reduces inflammation
  • reverses aging
  • builds collagen
  • replaces retinol

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a small (142 Da) cyclic amino-acid derivative — specifically (S)-2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid. Classified as an extremolyte: a natural molecule that certain microorganisms produce to survive extreme environmental stress (heat, cold, salinity, UV, desiccation). Extracted originally from Halomonas elongata, a bacterium isolated from the salt lakes of Wadi El Natrun, Egypt. Now produced industrially via biotechnology (bacterial fermentation) at high purity.

Development & history

  • Discovered in 1985 by Erwin Galinski and colleagues at the University of Bonn during study of salt-tolerant bacteria from Egyptian salt lakes.
  • Mechanism of action as osmolyte characterised through the 1990s.
  • Commercial cosmetic and medical-device applications developed by German biotech company bitop AG (now market leader in ectoin supply).
  • Entered mainstream cosmetics in the mid-2000s; used in medical-device products for atopic dermatitis and allergic rhinitis from the 2010s onward.
  • Today ectoin is present in a growing number of barrier-repair and sensitive-skin cosmetic formulations. Search volume for ectoin in skincare rose approximately 86% year-over-year in 2025, with the ingredient still relatively underused compared to hyped alternatives (exosomes, PDRN).

Mechanism (as proposed)

a small, highly water-soluble molecule that binds a shell of ordered water molecules around itself and, when applied to skin, around cellular membranes and proteins. This water shell stabilises membranes and proteins under stress (heat, UV, osmotic shift, oxidative attack) without directly interacting with them — the mechanism is described as preferential exclusion. In the stratum corneum this translates to: reduced transepidermal water loss, stabilised barrier lipids, protection of keratinocytes from UV and pollution-induced damage, and reduced release of inflammatory mediators. Ectoin does not enzymatically modify collagen, elastin, or pigmentation pathways — its benefit is defensive and hydrating, not regenerative.

Sources — 5 cited
01Graf R, et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol. 2008; 26(4):326-33.
02Marini A, et al. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol. 2014.
03Werkhauser N, et al. Treatment of allergic rhinitis with ectoine containing nasal spray and eye drops in comparison with azelastine. J Allergy (Cairo). 2014.
04Bilstein A, et al. Ectoin in the Treatment of Irritations and Inflammations of the Eye Surface. Biomed Res Int. 2021.
05Kauth M, Trusova O. Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review. Dermatol Ther (Heidelb). 2022.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 2026-07-07.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Matrixyl (Palmitoyl Pentapeptide-4)B
Peptide
GHK-Cu (Copper Tripeptide-1)B
Peptide
Explore by goal
Skin & aesthetic →
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COAHow we grade
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Ectoin — evidence, uses & status · Vallydia